Lovastatin dosage and administration: Difference between revisions
Created page with "__NOTOC__ {{Lovastatin}} {{CMG}}; {{AE}} {{SS}} ==Dosage and Administration== <ref name="dailymed.nlm.nih.gov">{{Cite web | last = | first = | title = ALTOPREV (LOVASTATI..." |
|||
| Line 5: | Line 5: | ||
==Dosage and Administration== | ==Dosage and Administration== | ||
<ref name="dailymed.nlm.nih.gov">{{Cite web | last = | first = | title = ALTOPREV (LOVASTATIN) TABLET, EXTENDED RELEASE [SHIONOGI INC.] | url = http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=e8b6ccc2-e6e7-45fd-ab66-c312bcbe2b01 | publisher = | date = | accessdate = 13 February 2014 }}</ref> | [[Hyperlipidemia]] (Heterozygous Familial and Nonfamilial) and Mixed [[Dyslipidemia]] (Fredrickson Types IIa and IIb) | ||
The recommended dosing range is 20-60 mg/day, in single doses taken in the evening at bedtime. | |||
===Elderly Patients=== | |||
The usual recommended starting dose in elderly patients (age≥65 years) is 20 mg once a day given in the evening at bedtime. Higher doses should be used only after careful consideration of the potential risks and benefits [see Use in Specific Populations (8.5) and Warnings and Precautions, Skeletal Muscle Effects (5.1)]. | |||
===Co-administration with Other Drugs=== | |||
Patients Taking [[Danazol]], [[Diltiazem]], [[Dronedarone]], or [[Verapamil]] | |||
The dose of Altoprev should not exceed 20 mg/day [see Warnings and Precautions, Skeletal Muscle Effects (5.1)]. | |||
Patients Taking [[Amiodarone]] | |||
The dose of Altoprev should not exceed 40 mg/day. [see Warnings and Precautions, Skeletal Muscle Effects (5.1) and Drug Interactions (7.6)]. | |||
===Dosage in Patients With Renal Impairment=== | |||
In patients with severe [[renal impairment]] (creatinine clearance <30 mL/min), dosage increases above 20 mg/day should only be considered if the expected benefit exceeds the increased risk of [[myopathy]]/[[rhabdomyolysis]]. [see Warnings and Precautions, Skeletal Muscle Effects (5.1) and Clinical Pharmacology, Pharmacokinetics (12.3)].</div><ref name="dailymed.nlm.nih.gov">{{Cite web | last = | first = | title = ALTOPREV (LOVASTATIN) TABLET, EXTENDED RELEASE [SHIONOGI INC.] | url = http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=e8b6ccc2-e6e7-45fd-ab66-c312bcbe2b01 | publisher = | date = | accessdate = 13 February 2014 }}</ref> | |||
==References== | ==References== | ||
Revision as of 00:42, 14 February 2014
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Sheng Shi, M.D. [2]
Dosage and Administration
Hyperlipidemia (Heterozygous Familial and Nonfamilial) and Mixed Dyslipidemia (Fredrickson Types IIa and IIb)
The recommended dosing range is 20-60 mg/day, in single doses taken in the evening at bedtime.
Elderly Patients
The usual recommended starting dose in elderly patients (age≥65 years) is 20 mg once a day given in the evening at bedtime. Higher doses should be used only after careful consideration of the potential risks and benefits [see Use in Specific Populations (8.5) and Warnings and Precautions, Skeletal Muscle Effects (5.1)].
Co-administration with Other Drugs
Patients Taking Danazol, Diltiazem, Dronedarone, or Verapamil The dose of Altoprev should not exceed 20 mg/day [see Warnings and Precautions, Skeletal Muscle Effects (5.1)].
Patients Taking Amiodarone
The dose of Altoprev should not exceed 40 mg/day. [see Warnings and Precautions, Skeletal Muscle Effects (5.1) and Drug Interactions (7.6)].
Dosage in Patients With Renal Impairment
In patients with severe renal impairment (creatinine clearance <30 mL/min), dosage increases above 20 mg/day should only be considered if the expected benefit exceeds the increased risk of myopathy/rhabdomyolysis. [see Warnings and Precautions, Skeletal Muscle Effects (5.1) and Clinical Pharmacology, Pharmacokinetics (12.3)].[1]
References
- ↑ "ALTOPREV (LOVASTATIN) TABLET, EXTENDED RELEASE [SHIONOGI INC.]". Retrieved 13 February 2014.